Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Luna Innovations Reports Fourth Quarter and Full Year 2007 Financial Results


Company Achieves 23% Revenue Growth for the Fourth Quarter 2007 and Full Year Revenue Expands by 43%; Fourth Quarter Product and License Revenue Growth of 64% and Full Year Increase of 117% Continues to Drive Gross Margin Expansion

Luna Innovations Reports Fourth Quarter and Full Year 2007 Financial Results

ROANOKE, VA | Posted on March 4th, 2008

Luna Innovations Incorporated (NASDAQ:LUNA) today announced its financial results for its fourth quarter and full year ended December 31, 2007.

As compared to the same quarter last year, revenues grew by 23%, from $8.0 million to $9.9 million, gross profit increased from $2.5 million to $3.7 million, and net loss per share declined from $0.27 to $0.11.

Kent Murphy, Chairman and Chief Executive Officer, provided this overview of Luna's results: "The fourth quarter proved to be a very successful one for us. Product and license sales increased by 64% year-over-year, which drove our overall gross margins from 31% in the fourth quarter of 2006 to 37% in our most recent quarter. With our growing backlog of new research opportunities and a promising pipeline of potential products, we remain well positioned to pursue our strategy and long-term business model of investing in the product side of our business."

Murphy added, "Advances in our nanotechnology are proving to be a particularly promising source of potential products. For example, in November we announced that we had been awarded a grant from the National Heart, Lung, and Blood Institute, one of the National Institutes of Health, to develop a new magnetic resonance imaging (MRI) contrast agent that could improve the diagnosis of coronary artery disease. The results of our efforts in this area are important because they could ultimately permit the evaluation of plaque levels without the use of potentially harmful ionizing radiation."

In remarking on Luna's exclusive carbon nanomaterial in relation to its use in MRI procedures, Murphy said, "Our tests continue to indicate that the Trimetasphere is very effective in keeping the gadolinium safely encapsulated, thereby reducing the risks that the Food and Drug Administration has been providing warnings about. The unique structure of a Trimetasphere-based contrast agent encloses the metallic signal molecule in such a way that it will not escape under physiological conditions and cause harm to the patient."

Murphy further remarked, "While there are many hurdles to overcome before any of these Trimetasphere-based agents could be approved for marketing, we are excited because we believe we have discovered a platform technology that has the potential to produce many new varieties of contrast agents, expanding the use of MRI to improve the diagnostics and the management of diseases where MRI is not currently being used."

Fourth Quarter Financial Highlights

* Total revenues for the fourth quarter of 2007 increased 23% compared to the fourth quarter of 2006.
* Product and license revenues represented 37% of total revenues in the fourth quarter of 2007, compared to 28% in the fourth quarter of 2006. Product and license revenues grew 64% to approximately $3.7 million in the fourth quarter of 2007, compared to $2.2 million in the fourth quarter of 2006.
* Gross profit for the fourth quarter of 2007 increased to $3.7 million, or 37% of total revenues, from $2.5 million, or 31% of total revenues, for the corresponding period of 2006. The improved gross profit was largely attributed to the higher proportion of product and license sales to total revenues.
* Net loss per share for the fourth quarter of 2007 was $0.11 per share, which is an improvement upon a loss per share of $0.27 for the fourth quarter of 2006.
* Cash and cash equivalents totaled $12.0 million at December 31, 2007, as compared to $12.5 million at September 30, 2007 and $17.9 million at December 31, 2006.

Fourth Quarter Business Highlights

Technology Development

* Awarded a grant from the National Heart, Lung, and Blood Institute to develop a new diagnostic agent that could improve the diagnosis of coronary artery disease, a condition that causes most heart attacks. Luna is investigating using its exclusive TRIMETASPHERE® platform which may provide the ability to use MRI to reveal plaque buildup in the arterial walls of the heart and possibly provide fine structural detail of the plaque.
* Made significant progress in the design of new therapeutic nanomedicines using our discoveries of functionalized nanomaterials and their beneficial effects on inflammatory and allergic responses in animal models.
* Attracted world-class experts to Luna's nanoWorks organization, including Vice President of Research and Development Krishan Kumar, Ph.D., an accomplished pharmaceutical manager and scientist with extensive pharmaceutical industry experience, and nanoImmunology Group Leader Chris Kepley, Ph.D., who for more than two decades has devoted his research to studying the mechanisms of allergic disease.
* Made significant progress in advancing the efficiencies of organic solar cells by applying patented TRIMETASPHERE® carbon nanomaterial technology, which could lead to the development of more efficient and less expensive alternative energy solutions. The U.S. Department of Energy's National Renewable Energy Laboratory (NREL) recently verified that using Luna's TRIMETASPHERE® nanomaterials significantly increase open circuit voltage in organic solar cells by more than 40% compared to today's standard C60 fullerenes.

Medical Devices

* Initiated clinical trials for Luna's EDAC® (Emboli Detection and Classification) QUANTIFIER under a recently announced agreement with Terumo Cardiovascular Systems.

Instrumentation, Test & Measurement Products

* Expanded the Luna Technologies division's offerings with two new product releases, including the PHOENIX™ 1000 laser, a tunable MEMS-based product designed to improve the performance of fiber optic test and measurement equipment, such as our Optical Backscatter Reflectometer platform, while reducing the size and cost of the equipment, allowing us to address broader markets such as handheld devices. Additionally, we introduced our PR™ 4400, an advanced precision reflectometer offering industry-leading micrometer spatial resolution, increased measurement range, high speed measurements, greater ease of use and a more cost-effective price point for optical component manufacturers.

Year-End Financial Highlights

* For the year ended December 31, 2007, total revenues grew $10.1 million, or 43%, to $33.7 million, compared to $23.5 million in 2006. Technology development revenue for 2007 increased $4.6 million, or 24%, over 2006. Product and license revenue was $10.3 million in 2007, representing a 117% increase over 2006. Gross profit increased to $12.3 million, or 37% of revenues, for 2007, from $7.2 million, or 31% of revenues, in 2006. Operating expenses were $20.6 million in 2007, compared to $17.2 million in 2006. The increase in year-over-year operating expenses reflects the company's strategy to increase its product portfolio and product sales. The company incurred a loss from operations of $8.3 million in 2007, versus a loss from operations of $10.0 million for the prior year.
* The net loss applicable to common stockholders for 2007 was $7.8 million, or $0.77 per share on a diluted basis, compared to the net loss applicable to common stockholders of $9.4 million, or $1.14 per share on a diluted basis, for the previous year.

Outlook for 2008

The company anticipates continued strong growth in both its product and license segment and its technology development division in 2008. For 2008, the company expects total revenue to be in the range of $40.0 million to $42.0 million, consisting of product and license revenue of $14.0 to $15.0 million and technology development revenue of $26.0 to $27.0 million. Also for 2008, the company anticipates a net loss in the range of $6.5 to $7.0 million. For the first quarter of 2008, the company expects revenue of approximately $8.8 million and a net loss of approximately $2.8 million. These expected results for the first quarter of 2008 reflect the historical seasonality in the company's revenue, particularly in product sales, where sales volumes each year have historically been lower in the first half of the year and higher in the second half of the year.

Conference Call Information

As previously announced, Luna Innovations will conduct an investor conference call at 5:00 p.m. (EST) today to discuss its financial results, business developments and expectations for 2008. The call can be accessed by dialing 1.866.356.4279 domestically or 1.617.597.5394 internationally prior to the start of the call. The access code is 52924878. The conference call will also be webcast live over the Internet. The webcast can be accessed by logging on to the "Investor Relations" section of the Luna Innovations website,, prior to the event. The webcast will be archived under the "Webcasts and Presentations" section of the Luna Innovations website for at least 30 days following the conference call.


About Luna Innovations Incorporated
Luna Innovations Incorporated ( develops and manufactures new-generation products for the healthcare, telecommunications, energy and defense markets. Luna's products are used to measure, monitor, protect and improve critical processes in the markets we serve. Through its disciplined commercialization business model, Luna has become a recognized leader in transitioning science to solutions. Luna is headquartered in Roanoke, Virginia.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This press release includes information that constitutes "forward-looking statements" made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including but not limited to: (i) the nanoWorks division's expected development of potential products, (ii) the TRIMETASPHERE(R) platform technology's ability to produce new varieties of contrast agents and solar cells or other alternative energy solutions, (iii) the company's anticipated growth in both its product and license and technology development divisions in 2008 and increased revenues and profitability in those areas, (iv) the company's plans to invest in the product side of its business, (v) the sales potential of new products, including the EDAC(R) QUANTIFIER, PHOENIX(TM) 1000 laser and the PR(TM) 4400, (vi) the company's expected backlog, (vii) the company's ability to continue to attract world class experts and (viii) the company's financial outlook for its first quarter 2008 and full fiscal year 2008, including expected revenues and net loss. The company attempts, whenever possible, to identify forward-looking statements by words such as "intends," "will," "plans," "anticipates," "expects," "may," "estimates," "believes," "should," "projects," or "continue," or the negative of those words and other comparable words. Similarly, statements that describe the company's business strategy, goals, prospects, opportunities, outlook, objectives, plans or intentions are also forward-looking statements. Actual events or results may differ materially from the expectations expressed in such forward-looking statements as a result of various factors, including risks and uncertainties, many of which are beyond the company's control. Factors that could cause actual results to differ materially from the expectations expressed in such forward-looking statements include, but are not limited to: the company's ability to manage its growth effectively; the company's ability to transition its revenue mix to product revenues and the company's limited experience in manufacturing products on a commercial scale; the company's ability to successfully identify market needs for new products; the company's ability to attract skilled employees; the company's continued reliance on contract research, including government grants and contracts available only to small businesses, for a significant portion of its revenue; the company's ability to remain eligible for small business government grants and contracts in the future; the company's ability to maintain sufficient proprietary rights to protect its technologies; the potential adverse effects of nanotechnology, whether real or perceived; and the potential limitations of regulatory requirements in obtaining clearance by the U.S. Food and Drug Administration or other regulatory agencies for the company's products. Additional factors that may affect the future results of the company are set forth in the company's quarterly and annual reports on Form 10-Q and Form 10-K, respectively, and other filings with the Securities and Exchange Commission ("SEC"), which are available at the SEC's website at, and at the Company's website at These risk factors are updated from time to time through the filing of periodic reports with the SEC. The statements made in this press release are based on information available to the company as of the date of this release and Luna Innovations undertakes no obligation to update any of the forward-looking statements herein after the date of this press release.

                    Luna Innovations Incorporated
                Consolidated Statements of Operations

                      Three Months Ended        Twelve Months Ended
                         December 31,              December 31,
                   ------------------------- -------------------------
                       2007         2006         2007         2006
                   ------------ ------------ ------------ ------------
                          (unaudited)        (unaudited)
    revenues       $ 6,265,004  $ 5,810,797  $23,356,456  $18,787,863
   Product and
    revenues         3,671,462    2,236,376   10,325,659    4,757,779
                   ------------ ------------ ------------ ------------
       revenues      9,936,466    8,047,173   33,682,115   23,545,642
Cost of revenues:
    research costs   4,626,536    4,540,201   16,546,140   14,140,605
   Product and
    license costs    1,648,822    1,026,427    4,819,825    2,221,396
                   ------------ ------------ ------------ ------------
      Total cost
       of revenues   6,275,358    5,566,628   21,365,965   16,362,001
                   ------------ ------------ ------------ ------------
Gross profit         3,661,108    2,480,545   12,316,150    7,183,641
Operating expense    4,870,622    5,344,918   20,570,479   17,150,195
                   ------------ ------------ ------------ ------------
Operating loss      (1,209,514)  (2,864,373)  (8,254,329)  (9,966,554)
                   ------------ ------------ ------------ ------------
Other income
   Other income
    (expense)          (18,112)      15,503       32,722       25,834
   Interest income
    / (expense),
    net                 76,231      170,024      371,991      515,818
                   ------------ ------------ ------------ ------------
Total other income
 (expense)              58,119      185,527      404,713      541,652
                   ------------ ------------ ------------ ------------
Loss before income
 taxes              (1,151,395)  (2,678,846)  (7,849,616)  (9,424,902)
Income tax expense
 (benefit)                   -            -            -       12,829
                   ------------ ------------ ------------ ------------
Net loss           $(1,151,395) $(2,678,846) $(7,849,616) $(9,437,731)
                   ============ ============ ============ ============
Net loss per
   Basic           $     (0.11) $     (0.27) $     (0.77) $     (1.14)
                   ============ ============ ============ ============
   Diluted         $     (0.11) $     (0.27) $     (0.77) $     (1.14)
                   ============ ============ ============ ============
Weighted average
   Basic            10,465,501    9,883,057   10,219,711    8,283,074
                   ============ ============ ============ ============
   Diluted          10,465,501    9,883,057   10,219,711    8,283,074
                   ============ ============ ============ ============

                    Luna Innovations Incorporated
                     Consolidated Balance Sheets

                                          December 31,   December 31,
                                              2007           2006
                                         -------------- --------------
Assets                                    (unaudited)
Current assets
   Cash and cash equivalents             $  12,046,945  $  17,866,753
   Accounts receivable, net                  9,716,610      7,233,406
   Refundable income taxes                     396,062        396,062
   Inventory                                 1,675,239        843,294
   Other current assets                        333,105        503,703
                                         -------------- --------------
      Total current assets                  24,167,961     26,843,218
Property and equipment, net                  5,859,515      5,730,094
Intangible assets, net                       1,911,132      2,031,489
Deferred tax asset                             600,000        600,000
Other assets                                    10,270         12,413
                                         -------------- --------------
         Total assets                    $  32,548,878  $  35,217,214
                                         ============== ==============
Liabilities and stockholders' equity
Current liabilities
   Current portion of capital lease
    obligation                           $      23,885  $      85,378
   Current portion of long-term debt
    obligation                                       -        214,955
   Accounts payable                          3,024,973      2,757,381
   Accrued liabilities                       5,331,798      3,627,277
   Deferred credits                          1,672,400        874,676
                                         -------------- --------------
      Total current liabilities             10,053,056      7,559,667
Long-term capital lease obligation               4,671         27,873
Long-term debt obligation                    5,000,000      5,000,000
Deferred credits and other long term
 liabilities                                   354,418        554,418
                                         -------------- --------------
      Total liabilities                     15,412,145     13,141,958
                                         -------------- --------------
Stockholders' equity:
   Preferred stock, par value $0.001,
    5,000,000 shares authorized at
    December 31, 2007, no shares issued
    and outstanding at December 31, 2007             -              -
   Common stock
      Common stock, par value $0.001,
       100,000,000 shares authorized at
       December 31, 2007 and December
       31, 2006,10,704,456 shares issued
       and outstanding at December 31,
       2007                                     10,704          9,912
   Additional paid-in capital               34,496,063     31,585,762
   Accumulated deficit                     (17,370,034)    (9,520,418)
                                         -------------- --------------
      Total stockholders' equity            17,136,733     22,075,256
                                         -------------- --------------
         Total liabilities and
          stockholders' equity           $  32,548,878  $  35,217,214
                                         ============== ==============

                    Luna Innovations Incorporated
                Consolidated Statements of Cash Flows

                                              Twelve Months Ended
                                                 December 31,
                                              2007           2006
                                         -------------- --------------
Cash flows used in operating activities
   Net loss                              $  (7,849,616) $  (9,437,731)
   Adjustments to reconcile net loss to
    net cash provided by operating
      Depreciation and amortization          1,780,877      1,141,115
      Deferred income taxes                          -              -
      Share-based compensation               2,425,114      1,772,607
   Change in assets and liabilities:
      Accounts receivable                   (2,483,204)    (2,103,495)
      Refundable income taxes                        -        118,735
      Other assets                            (659,205)      (654,563)
      Accounts payable and accrued
       expenses                              1,972,111        527,098
      Deferred revenues                        597,724       (479,299)
                                         -------------- --------------
         Net cash used in operating
          activities                        (4,216,199)    (9,115,533)
                                         -------------- --------------
Cash flows used in investing activities
   Acquisition of property and equipment    (1,375,612)    (2,834,385)
   Intangible property costs                  (414,328)      (558,909)
                                         -------------- --------------
         Net cash used in investing
          activities                        (1,789,940)    (3,393,294)
                                         -------------- --------------
Cash flows from financing activities
   Net payments on line of credit
   Payments on debt obligation                (214,953)             -
   Payments on capital lease obligations       (84,695)      (102,703)
   Proceeds from the issuance of common
    stock, net                                       -     17,866,241
   Proceeds from the exercise of options
    and warrants                               485,979         97,203
                                         -------------- --------------
         Net cash from financing
          activities                           186,331     17,860,741
                                         -------------- --------------
Net change in cash                          (5,819,808)     5,351,914
Cash - beginning of period                  17,866,753     12,514,839
                                         -------------- --------------
Cash - end of period                     $  12,046,945  $  17,866,753
                                         ============== ==============
Supplemental disclosure of cash flow
Cash paid for interest                   $           -  $      45,341
Cash paid for income taxes               $           -  $      12,829

For more information, please click here

Media Contact:
Luna Innovations Incorporated
Karin Clark, 1-540-769-8400
Investor Contact:
Qorvis Communications
Sally Beerbower, 1-703-744-7800

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Pulses of electrons manipulate nanomagnets and store information: Scientists use electron pulses to create and manipulate nanoscale magnetic excitations that can store data July 21st, 2017

The first light atomic nucleus with a second face July 20th, 2017

Semiliquid chains pulled out of a sea of microparticles July 20th, 2017

Harnessing light to drive chemical reactions July 19th, 2017


Pulses of electrons manipulate nanomagnets and store information: Scientists use electron pulses to create and manipulate nanoscale magnetic excitations that can store data July 21st, 2017

Probiotics: Novel biosynthetic tool to develop metallic nanoparticles: This research article by Dr. Nida Akhtar et al has been published in Recent Patents on Drug Delivery & Formulation, Volume 11, Issue 1, 2017 July 20th, 2017

The first light atomic nucleus with a second face July 20th, 2017

Semiliquid chains pulled out of a sea of microparticles July 20th, 2017

Financial Reports

Nanometrics to Announce Second Quarter Financial Results on August 1, 2017 July 14th, 2017

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results April 27th, 2017

Nanometrics to Announce First Quarter Financial Results on May 2, 2017 April 11th, 2017

Harris & Harris Group Issues Its Financial Statements as of December 31, 2016, Posts Its Annual Shareholder Letter, And Will Host a Conference Call for Shareholders on Friday, March 17, 2017 March 15th, 2017

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project